Holen Sie sich die Stockscreener-App
3.53
2.22%
-0.08
Neurobo Pharmaceuticals Inc Aktie (NRBO) Neueste Nachrichten
NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Zacks Small Cap Research
NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Yahoo Finance
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Longview News-Journal
NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial - Clinical Trials Arena
NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial - Yahoo Finance
NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial - TipRanks
NeuroBo partners for long-acting obesity treatment - Investing.com India
NeuroBo Partners for Monthly Dual-Action Diabetes Drug Development - TipRanks
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - StockTitan
NeuroBo licenses diabetic neuropathy drug to MThera Pharma By Investing.com - Investing.com Nigeria
NeuroBo licenses diabetic neuropathy drug to MThera Pharma By Investing.com - Investing.com Canada
NeuroBo licenses diabetic neuropathy drug to MThera Pharma - Investing.com
NeuroBo Signs Exclusive License Agreement With MTHERA For NB-01 - Contract Pharma
NeuroBo Pharmaceuticals Strikes Licensing Deal for NB-01 - TipRanks
NeuroBo licenses diabetic neuropathy drug to MThera Pharma By Investing.com - Investing.com UK
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) Shares Down 3.4% - Defense World
BIX 2024: From graveyard to breakthrough, MASH candidates on rise - BioWorld Online
NeuroBo Pharmaceuticals Releases Corporate Presentation Update - TipRanks
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July - Quantisnow
Amendment: Large owner Dong-A St Co., Ltd bought $10,000,003 worth of shares (2,544,530 units at $3.93), increasing direct ownership by 91% to 5,348,229 units (SEC Form 4) - Quantisnow
[Top Trends] Homozygous Familial Hypercholesterolemia Epidemiology Market | NeuroBo Pharmaceuticals, Aegerion Pharmaceutical, Arrowhead Pharmaceuticals – Economica - Economica
NeuroBo Pharmaceuticals | The Pharmaletter - The Pharma Letter
NRBO: DA-1726 Shows Superiority to Survodutide in Pre-Clinical Models… - Zacks Small Cap Research
NRBO: DA-1726 Shows Superiority to Survodutide in Pre-Clinical Models… - Yahoo Finance
Huge Insider Buying at a Warren Buffett Pick and 5 Other Stocks - 24/7 Wall St.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) versus Jazz Pharmaceuticals (NASDAQ:JAZZ) Financial Contrast - Defense World
NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors - The Globe and Mail
NeuroBo doses first subject in Part 2 of Phase I obesity treatment trial - Yahoo Finance
NeuroBo doses first subject in Part 2 of Phase I obesity treatment trial - Clinical Trials Arena
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Major Shareholder St Co. Ltd Dong-A Acquires 2544530 Shares - Defense World
Evaxion Biotech advances in personalized cancer vaccine By Investing.com - Investing.com India
NeuroBo starts obesity drug trial ahead of schedule - Investing.com
Chipotle shares maintain buy rating, price target adjusted on recent stock split By Investing.com - Investing.com India
NeuroBo starts obesity drug trial ahead of schedule By Investing.com - Investing.com India
NeuroBo starts obesity drug trial ahead of schedule By Investing.com - Investing.com UK
DraftKings stock target cut, maintains Buy rating By Investing.com - Investing.com
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying - MSN
NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the ... - StockTitan
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying - Benzinga
Earnings call: FedEx reports strong Q4 with focus on efficiency and growth By Investing.com - Investing.com UK
Continued Pre-Market Rally For NeuroBo (NRBO) Stock - Stocks Telegraph
Dong-A ST Co. acquires $7.96m of NeuroBo Pharmaceuticals shares - Investing.com India
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered ... - StockTitan
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered ... - Lelezard
Pool Corp stock target cut, Outperform rating on lower revenue outlook By Investing.com - Investing.com Australia
TD Cowen maintains buy on Humacyte with $7.50 target By Investing.com - Investing.com Canada
Dong-A ST Co. acquires $7.96m of NeuroBo Pharmaceuticals shares By Investing.com - Investing.com Australia
Dong-A ST Co. acquires $7.96m of NeuroBo Pharmaceuticals shares - Investing.com
NeuroBo secures $20 million in private placement - Investing.com India
NeuroBo secures $20 million in private placement By Investing.com - Investing.com
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com UK
NeuroBo Pharmaceuticals Shares Rise on Positive Results for Weight-Loss Drug - MarketWatch
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid ... - Quantisnow
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models - PR Newswire
Peripheral Neuropathy Treatment Market Will Show the Highest - openPR
ChargePoint executive sells over $13k in company stock By Investing.com - Investing.com
1.26%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):